Nutritional and Metabolic Diseases

Symptoms and General Pathology

All Conditions

Dehydration

Water-Electrolyte Imbalance

Metabolic Diseases

Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily

Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

Saline

100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

Eduardo Bruera, MD

The goal of this clinical research study is to learn whether being hydrated (given liquids) through a catheter in a vein or in the tissue under the skin can improve symptoms of dehydration.

Objectives:

1.1 Determine whether parenteral hydration is superior to placebo in improving symptoms associated with dehydration (such as fatigue, myoclonus, sedation, and hallucinations) in advanced cancer patients receiving hospice care.

1.2 Determine whether parenteral hydration is superior to placebo in delaying the onset or reducing the severity of delirium in patients with advanced cancer receiving hospice care.

1.3 Describe the meaning patients and primary caregivers attribute to dehydration and re-hydration at the end of patient's lives.

For Caregivers:

Symptoms of dehydration may include fatigue, muscle contractions, the need for sedation (calming medication), and hallucinations (where something is sensed that is not actually there). Hydration allows the body to get rid of the waste products from medications and other chemicals. When the fluid levels in the body are increased, the brain function may directly improve.

If the patient under your care is found to be eligible to take part in this study, he or she will be randomly assigned (as in the toss of the coin) to one of 2 groups. Participants in Group 1 will receive normal saline (salt water) once a day. Participants in Group 2 will receive a lower amount of normal saline once a day. This lower amount is small enough to be considered a placebo. Doctors call something a placebo if it looks like the substance being tested but has no active ingredients (or in this case, few active ingredients).

Both you and the patient will be asked to complete a number of questionnaires at the beginning of the study, on Days 1-7, and then every 3-5 days after that. Your questionnaires will ask about the feelings you may have about hydration and the care that you are providing to the patient. Each day's questionnaires will take about 30 minutes.

Both you and the patient will also be interviewed by researchers at the beginning of the study and on Day 4 (+/- 2 days). The interviews will include questions about what it has been like for the patient to get fluids, whether the fluid was more like food or medicine, whether the patient has ever gotten dehydrated, and how you manage the patient's care. The interviews should each take about 30 minutes. The interviews in this study will be audio taped so the information can be studied by researchers. Only the research staff will listen to the audio tape of the interviews.

If the patient goes off study, your participation in the study will be over.

This is an investigational study. Up to 150 patients and 150 caregivers will take part in this study. All will be enrolled at M. D. Anderson.

For Patients:

Before you can start treatment on this study, you will have "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. You will be asked to complete a questionnaire. It will ask questions about your cancer diagnoses, the medications you are taking, and the symptoms you are having. The questionnaire also asks about your memory of being dehydrated, what it was like for you to get fluids, how you manage your care, and whether the fluid was more like food or medicine. It should take about 30 minutes to complete.

Both you and your caregiver will also be interviewed by researchers. There will be questions about what it has been like for you to get fluids, whether the fluid was more like food or medicine, and whether you have ever gotten dehydrated. Each interview should take about 30 minutes. The interviews in this study will be audio taped so the information can be studied by researchers.

The study staff will also check you for symptoms of muscle contraction, one of the signs of dehydration. The study staff will videotape your face, arms, hands, legs and toes for a total 3-5 minutes on Days 1, 4, and 7, and then every 3-5 days after that.

As part of the screening tests, you will also have blood drawn (about 2 teaspoons) for routine tests. You will be asked questions about your ability to perform daily activities (performance status evaluation). You will be asked about any side effects you may have, including muscle contractions. You will also be asked to list any pain medications or other medications that you take.

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of the coin) to one of two groups. Participants in Group 1 will receive normal saline (salt water) once a day. Participants in Group 2 will receive a lower amount of normal saline once a day. This lower amount is small enough to be considered a placebo. Doctors call something a placebo if it looks like the substance being tested but has no active ingredients (or in this case, few active ingredients). You will have an equal chance of being placed in either group. Neither you nor any of the medical staff or researchers on this study will know which dose you are receiving.

The research nurse will ask you to complete several questionnaires that ask questions about dehydration and the symptoms you may have experienced, including fatigue. The questionnaires will be completed on Days 1-7, and then every 3-5 days after that. In total, each day's questionnaires should take about 30 minutes. Your caregiver will also be asked about his or her memory of your dehydration. On Day 7, you will have blood drawn (about 2 teaspoons) for routine tests.

Both you and your caregiver will also be interviewed by researchers on Day 4 (+/- 2 days), and then every 3-5 days after that. The interviews will be like the ones at screening.

Starting on Day 1 of the study, you will receive saline through a catheter in a vein (over 4 hours) every day. If you already have a central venous catheter, you will receive the saline through that catheter. If you do not have a central venous catheter, the saline will be infused under the skin. Either way, the infusion will last about 4 hours.

During each infusion, an infusion research nurse will check to make sure that the saline is given properly. This nurse will know which treatment group you have been assigned to.

Every day, the research nurse will ask you about the dehydration and any side effects you may have. Every day, the research nurse will also check the place where the infusion is given to make sure there is no infection.

On Days 1-7 and then every 3-5 days, the research nurse will also check for any dehydration symptoms including the need for sedation, any restless feelings or actions, and/or muscle contractions. You will have a performance status evaluation daily. On Days 1-7, the research nurse will ask about any pain medications or other medications that you have taken.

Every day, 2 hours \[+/- 3 hours\] after the infusion ends, you will also be checked by an assessment research nurse who will not know which treatment group you are in. The assessment research nurse will ask about any symptoms you may have. The study staff will also check you for symptoms of muscle contraction, one of the signs of dehydration. The study staff will videotape your face, arms, hands, legs and toes for a total 3-5 minutes on Days 1, 4, and 7, and then every 3-5 days after that.

You may remain on study to receive the daily infusions for as long as you are benefitting up to Day 14 \[+/- 3 days\]. On Day 14 \[+/- 3 days\] you will be taken off study, and you will have off study assessments, which include questions about your symptoms including fatigue, performance status, medications you are taking, and dehydration symptoms. If intolerable side effects occur, you will be taken off study and given appropriate medical care. If you wish to continue receiving hydration fluids after you are taken off study \[Day 14 +/- 3 days\], you may discuss this option with your attending hospice physician. You may receive a liter of normal saline each day under the skin. Treatment will be given by hospice nurse. Fluid will be provided to you free of charge.

This is an investigational study. Up to 150 patients and 150 caregivers will take part in this study. All will be enrolled at M. D. Anderson.

Parenteral Hydration in Advanced Cancer Patients

Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial

Symptom burden, assessed using the Edmonton Symptom assessment scale, which has been validated in the cancer population. Participants are asked to rate the severity of their symptoms over the previous 24 hours using a numerical rating scale of 0-10, with 0 meaning that the symptom is absent and 10 meaning the worst possible symptom. The mean is a composite outcome where change in the sum of 4 dehydration symptoms (fatigue, myoclonus, sedation and hallucinations) between day 4 and baseline ranged from 0-40 daily. The reported value was the mean of average change in patients' scores per group.

Participants rated delirium, quality of life, and overall survival using Richmond agitation sedition scale (RASS) where +4 is "Combative" to -5 is "Unarousable"; Memorial delirium assessment scale (MDAS), a ten-item, clinician-rated scale from 0 (none) to 3 (severe) for severity of delirium, for a total range of 0-30; and Unified Myoclonus Rating Scale (UMRS) 5-functional scores rated 0 to 4, for a total range of 0-20 where higher scores indicate more severe involuntary movements. Higher scores indicate worse outcomes for each scale, i.e. RASS more agitation, MDAS more delirium and UMRS more severe involuntary movements. The mean represents change in combined participant daily scores for each scale between Baseline and Day 4 assessments then separately Day 7 assessments. Reported value is mean of average change in patients' scores per group. Reported values reflect changes from baseline, either median decreases (less than 0), no change (0) or increases (greater than 0).

Change between Day 7 to Baseline in FACIT-F (Functional Assessment of Chronic illness Therapy-Fatigue) \& FACT-G (Functional Assessment of Cancer Therapy-General) scores. Participants rate quality of life using FACT-G consisting of 33 questions with 5 domains assessing physical and social, emotional \& functional well being \& relationship with physician, remaining 5 assess extent to which each domain affects overall quality of life on 5-point scale from 0 (not at all) to 4 (very much); total score obtained by summing individual subscale scores (0-132). FACIT-F consists of 13 items where participants rate intensity of fatigue \& its related symptoms on a scale of 0-4 from 0 "not at all" to 4 "very much." The responses to FACIT fatigue questionnaire are each measured on 4-point Likert scale with total score ranges from 0 to 52. High scores represent less fatigue. Reported is the mean change of the summed value of all reported scores for the FACT-G or the FACIT-F from baseline to Day 7.

Secondary outcomes included delirium, quality of life, and overall survival. The Nursing delirium screening scale (NuDESC) was used to assess delirium. NuDESC is a validated observational instrument conducted by research staff based on input from family caregivers. Five symptoms (disorientation, inappropriate behavior, inappropriate communication, illusions or hallucinations, and psychomotor retardation) are each given a score from 0 to 2, for a possible total score of 10. A higher NuDESC score indicates increased symptoms of delirium. It was observed a trend for lesser decline (delirium) in the hydration group, and significant worsening of night-time NuDESC scores in the placebo group.

Dehydration was assessed by using the Dehydration Assessment Scale on the basis of three physical findings, moisture on the mucous membranes of the mouth (0=moist, 1=somewhat dry, 2=dry), axillary moisture (0=moist, 1=dry) and sunkenness of the eyes (0=normal, 1=slight sunken, 2=sunken). These signs are selected due to their significant correlations with biological dehydration, as previously confirmed by elderly patients. The dehydration score (range 0-7) is calculated as the total of these 3 scores, a higher score indicates a higher level of dehydration. The reported value was the mean of average change in patients' scores per group.

National Institutes of Health (NIH)

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Hydration

Placebo

Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

Hydration: Normal Saline (Salt Water)

Placebo: Lower Saline

Total

Age, Continuous

<=18 years

Between 18 and 65 years

>=65 years

Age, Customized

Sex: Female, Male

United States

Region of Enrollment

Study had a planned sample size of 150 participants but due to funding issues recruitment was halted after 129 patients; additionally, participants with delirium or severe dehydration were excluded for logistic purposes.

Dr. Eduardo Bruera, MD / Professor

Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

Participant Reduced Symptom Burden

RASS

MDAS

UMRS

Hydration (Baseline and Day 4)

Placebo (Baseline and Day 4)

Hydration (Baseline and Day 7)

Placebo (Baseline and Day 7)

Reduced Symptom Burden as Measured by RASS, MDAS and UMRS

FACT-G

FACIT-F

Change in Quality of Life and Fatigue as Measured by FACIT-F and FACT-G From Baseline to Day 7

NuDESC Day

NuDESC Evening

NuDESC Night

Reduced Symptom Burden (From Baseline to 7 Days Post Infusion)

Change in Dehydration as Measured by Dehydration Assessment Scale

Overall Study

Behaviors and Mental Disorders

Depression

Caregiver Burden

Depressive Disorder

Mental Disorders

Pain

Psychotic Disorders

Behavioral Symptoms

Central Nervous System Stimulants

All Drugs and Chemicals

Psychotropic Drugs

Anti-Dyskinesia Agents

Cardiotonic Agents

Escitalopram

Methylphenidate

Citalopram

Sertraline

Fluoxetine

Antidepressive Agents

Bupropion

Selective Serotonin Reuptake Inhibitors

Paroxetine

Dexetimide

Venlafaxine Hydrochloride

Serotonin

Dopamine

Dopamine Uptake Inhibitors

Dopamine Agents

Neurotransmitter Agents

Serotonin Receptor Agonists

During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.

During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.

Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.

If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.

Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid.

Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.

If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention.

Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.

A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion

Selective Serotonin Uptake Inhibitor (SSRI)

Linda K. Ganzini, MD MPH

The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.

Background: Major depressive disorder can be diagnosed in between 5% and 26% of terminally ill patients. This disorder causes suffering, and is associated with suicidality, increased pain, and increased caregiver burden and caregiver depression. Treatment of depression in cancer patients in hospice and palliative care is complicated by shortened life expectancy. Currently-approved antidepressants take several weeks to be effective. Methylphenidate has been reported in case series and very small randomized trials in patients without cancer as a rapidly effective treatment for depression in medically ill patients. There are no randomized controlled trials to test this agent in terminally ill cancer patients.

Objectives: (1) To determine the effectiveness and safety of methylphenidate for depression treatment in cancer patients receiving hospice and palliative care, (2) to explore whether successful treatment of depression is associated with improved quality of life, and (3) to explore whether effective treatment of depression influences caregiver depression and caregiver burden.

Methods: We will conduct an 18-day randomized, double-blind, fixed-dose (10 mg bid), placebo-controlled clinical trial of methylphenidate for depression in eligible veteran and non-veteran cancer patients with advanced cancer in the following settings: inpatient and outpatient hospice, inpatient and outpatient palliative care, and inpatient and outpatient cancer clinics. We will determine whether improvement in depression is mediated by decreased pain and document the safety and tolerability of methylphenidate in these patients. We will explore whether improvement in depression results in improved quality of life for these patients, and decreases caregiver depression and burden.

Eligible patients who answer yes to the question "are you sad or depressed" will be invited to participate. They will complete measures of depression \[Structured Clinical Interview for Diagnosis (SCID), Montgomery-Asberg Depression Rating Scale (MADRS) as primary outcome, Hospital Anxiety and Depression Scale (HADS) as secondary outcome\], quality of life, pain, and cognition at baseline. MADRS scores must be greater than 19 and SCID positive for depression at study entry. Subjects will be randomized to either methylphenidate plus an SSRI, or placebo plus an SSRI. Subjects may continue any previously prescribed SSRI, or will be prescribed citalopram if untreated. Participants will be evaluated with the same measures as baseline on days 3, 6, 12 and 18 of the study. In an open label portion of the study, methylphenidate-treated patients whose depression has improved will be followed up to 2 months. Cox proportional hazard analysis will be used to analyze the primary outcome. An estimated 104 subjects will be entered over five years. Caregivers will complete measures of depression and caregiver burden at days 0 and 18.

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

Methylphenidate for Depressed Cancer Patients in Hospice

Days to a 50% or greater reduction in initial Montgomery-Asberg Depression Rating Scale (MADRS) score.

Oregon Health and Science University

US Department of Veterans Affairs

During the 18-day blind treatment period, subjects will be prescribed Methylphenidate 5-10 mg twice per day and Selective Serotonin Reuptake Inhibitor. Subjects receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not already receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.

Methylphenidate + SSRI

During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and Selective Serotonin Reuptake Inhibitor. Subjects receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not already receiving a SSRI will be prescribed 10-20 mg per day Citalopram.

Placebo + SSRI

Age, Categorical

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Married

Single

Divorced

Widowed

Partnership

Marital Status

Education

Gastrointestinal

Pulmonary

Urogenital

Breast

Prostate

Neurological

Dermatological

Head and Neck

Hematological

Type of Cancer

The number of baseline participants is the number of subjects who received the intervention

Frequency threshold for reporting nonserious adverse events was not determined at the start of the study, but a % was required to be entered in order to complete the adverse event module

Dr. Linda Ganzini

The number of participants analyzed is the number of who received the intervention

Days to Remission of Depression

Received Intervention

Open Label for SSRI+Methylphenidate Arm

complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.

complementary and alternative therapy

The aim of the study is to assess Prevalence of complementary and alternative therapy use by adult patients from the area of Silesian agglomeration (Poland) with advanced, metastatic cancer disease who were admitted to "Pro Salute" Hospice for ambulatory palliative care between July 2017 and September 2018

The research team developed the CAT (complementary and alternative therapy) screening tool to obtain information about CAM use from patients. The screening tool was based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. CAT were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.

The questionaire was tailored to meet the objectives of this study and to be adjusted to hospice patients specifics. It was piloted on the group of 25 patients, resulting in some vocabulary changes. The final questionnaire consists of 25 multiple-choice, semi-structured questions and takes about 15 min to complete. For each general CAM category the detailed information was collected on the type of specific therapy that was used. Patients were considered as CAM users if they have used at least one therapy from at least one of the categories during the period of 12 months prior to the screening. Patients were asked to specify the reasons for CAT usage, experienced effects of the therapy, stage at which patients considered using CAM

Use of CAM by Hospice Oncology Patients During Ambulatory Palliative Care

Use of Complementary and Alternative Medicine by Hospice Oncology Patients During Ambulatory Palliative Care

Presence and quantity of patients using any CAM therapies -The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Presence and quantity of patients using biologically based therapies - The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Presence and quantity of patients using mind/body therapies - The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Presence and quantity of patients using manipulative and body-based therapies - The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Presence and quantity of patients using Energy therapies - The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Presence and quantity of patients using alternative medical systems - The research team developed the CAT screening tool based on a The National Center for Complementary and Alternative Medicine's (NCCAM) classification of CAM. Questionnaire consists of 25 multiple-choice, semi-structured questions and gives the result in the form of a percentage

Silesian University of Medicine

Principal Investigator

Shabbir Syed-Abdul, PhD

Shabbir Syed Abdul

The purpose of this study is to develop a novel deep-learning-based survival prediction model employing patient activity data recorded by a wearable device.

This study aims to develop a deep-learning-based survival prediction model that utilizes patient movement data upon admission to predict their clinical outcomes: either death or discharge with stable condition. Objective data of the patients are recorded by a wearable device and documented as parameters of physical activity, angle, and spin. In addition to objective data, the investigators also document patients' Karnofsky Performance Status assessed subjectively by clinical doctors. Finally, the investigators aim to explore and describe the applicability, potential, and limitations of the survival prediction model based on patient movement data as a simple prognostic parameter in clinical settings.

Artificial Intelligence-based Mortality Prediction Among Cancer Patients in the Hospice Ward

Artificial Intelligence-based Activity Recognition and Mortality Prediction Using Circadian Rhythm, Among Cancer Patients in the Hospice Ward

The primary outcome of the study will be to evaluate whether the analysis of the movement data captured using actigraphy device can help to predict clinical outcomes either deceased or discharged alive from hospital, with a high specificity and sensitivity, using Artificial Intelligence based prediction modelling.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Parenteral Hydration in Advanced Cancer Patients	NCT00423722	Advanced Cancer Dehydration	Saline Saline	18 Years -	M.D. Anderson Cancer Center
Parenteral Hydration in Advanced Cancer Patients	NCT00423722	Advanced Cancer Dehydration	Saline Saline	18 Years -	M.D. Anderson Cancer Center
Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	NCT00129467	Depression Palliative Care Cancer Mental Disorder	Methylphenidate Placebo Selective Serot...	18 Years -	VA Office of Research and Development
Parenteral Hydration in Advanced Cancer Patients	NCT00423722	Advanced Cancer Dehydration	Saline Saline	18 Years -	M.D. Anderson Cancer Center
Use of CAM by Hospice Oncology Patients During Ambulatory Palliative Care	NCT03747172	Complementary A... Complementary A... Hospice Care	complementary a...	18 Years - 90 Years	Silesian University of Medicine
Artificial Intelligence-based Mortality Prediction Among Cancer Patients in the Hospice Ward	NCT04883879	End Stage Cance...		20 Years -	Taipei Medical University

Spots Global Cancer Trial Database for hospice care

Every month we try and update this database with for hospice care cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.